{
    "info": {
        "nct_id": "NCT04141995",
        "official_title": "A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic Cancer",
        "inclusion_criteria": "* Pathologically confirmed pancreatic adenocarcinoma. Participants must have resectable disease with no evidence of distant metastasis.\n* 19 years of age or older.\n* Eastern Cooperative Oncology Group (ECOG) Performance Scale (PS) of 0-1 (fully active to restricted in strenuous activity).\n* Chemotherapy for malignancies other than pancreatic cancer completed > 5 years ago and is no evidence of the prior malignancy at time of study entry.\n* Radiographically assessable disease.\n* Initial absolute neutrophil count (ANC) greater than or equal to 1000/μL and platelet count greater than or equal to 100,000/μL.\n* Normal serum potassium, magnesium and corrected calcium level.\n* Serum creatinine less than or equal to 2.0 mg/dL.\n* Total bilirubin <= 1.5 mg/dL [unless the participant has Gilbert disease with elevated non-conjugated (indirect) bilirubin; in such cases, the indirect bilirubin should be <= 1.0 mg/dL].\n* If participant has biliary obstruction, biliary decompression will be required. Either endoscopic placement of biliary stent or percutaneous transhepatic drainage are acceptable. Once biliary drainage has been established, institution of FOLFOX therapy may proceed when the total bilirubin falls to <= 5.0 mg/dL. The addition of irinotecan will be delayed until the total bilirubin is 1.5 mg/dL or lower.\n* Awareness of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.\n* No prior chemotherapy for pancreatic cancer.\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
        "exclusion_criteria": "* Unable to undergo staging laparoscopy, such as a prior history of multiple abdominal operations in which laparoscopy may not be technically feasible or might be potentially harmful.\n* A contra-indication to receiving digoxin therapy (e.g., AV block, sick sinus syndrome, bradycardia, hypersensitivity to digoxin or digitalis preparations).\n* Uncontrolled inter-current illness including, but not limited to ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or serious, uncontrolled cardiac arrhythmia, that might jeopardize the ability of the participant to receive the therapy in this study with reasonable safety.\n* Pregnant and nursing women (risk posed by chemotherapy agents). Female participants of childbearing potential must have a negative urine pregnancy test before receiving the first dose of study drug.\n* Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, adequately treated non-invasive carcinomas, or other cancers from which the participant has been disease-free least 5 years.\n* Known HIV infection or active hepatitis B or C infection (concern for increased toxicity).\n* Active autoimmune disease [e.g., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ulcerative colitis (UC), Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis (AS)].\n* Recognized acquired, hereditary, or congenital immunodeficiency disease including cellular immunodeficienciess, hypogammaglobulinemia, or dysgammaglobulinemia.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* No prior chemotherapy for pancreatic cancer.",
            "criterions": [
                {
                    "exact_snippets": "No prior chemotherapy for pancreatic cancer",
                    "criterion": "prior chemotherapy for pancreatic cancer",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine less than or equal to 2.0 mg/dL.",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine less than or equal to 2.0 mg/dL",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If participant has biliary obstruction, biliary decompression will be required. Either endoscopic placement of biliary stent or percutaneous transhepatic drainage are acceptable. Once biliary drainage has been established, institution of FOLFOX therapy may proceed when the total bilirubin falls to <= 5.0 mg/dL. The addition of irinotecan will be delayed until the total bilirubin is 1.5 mg/dL or lower.",
            "criterions": [
                {
                    "exact_snippets": "If participant has biliary obstruction, biliary decompression will be required.",
                    "criterion": "biliary obstruction",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "biliary decompression will be required. Either endoscopic placement of biliary stent or percutaneous transhepatic drainage are acceptable.",
                    "criterion": "biliary decompression",
                    "requirements": [
                        {
                            "requirement_type": "procedure",
                            "expected_value": [
                                "endoscopic placement of biliary stent",
                                "percutaneous transhepatic drainage"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Once biliary drainage has been established, institution of FOLFOX therapy may proceed when the total bilirubin falls to <= 5.0 mg/dL.",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "The addition of irinotecan will be delayed until the total bilirubin is 1.5 mg/dL or lower.",
                    "criterion": "total bilirubin (for irinotecan)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin <= 1.5 mg/dL [unless the participant has Gilbert disease with elevated non-conjugated (indirect) bilirubin; in such cases, the indirect bilirubin should be <= 1.0 mg/dL].",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin <= 1.5 mg/dL",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the participant has Gilbert disease ... indirect bilirubin should be <= 1.0 mg/dL",
                    "criterion": "indirect bilirubin (in participants with Gilbert disease)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Normal serum potassium, magnesium and corrected calcium level.",
            "criterions": [
                {
                    "exact_snippets": "Normal serum potassium",
                    "criterion": "serum potassium level",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Normal serum ... magnesium",
                    "criterion": "serum magnesium level",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "normal"
                        }
                    ]
                },
                {
                    "exact_snippets": "Normal serum ... corrected calcium level",
                    "criterion": "serum corrected calcium level",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": "normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 19 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 19 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 19,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Scale (PS) of 0-1 (fully active to restricted in strenuous activity).",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Scale (PS) of 0-1 (fully active to restricted in strenuous activity)",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Initial absolute neutrophil count (ANC) greater than or equal to 1000/μL and platelet count greater than or equal to 100,000/μL.",
            "criterions": [
                {
                    "exact_snippets": "Initial absolute neutrophil count (ANC) greater than or equal to 1000/μL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "/μL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "platelet count greater than or equal to 100,000/μL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "/μL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiographically assessable disease.",
            "criterions": [
                {
                    "exact_snippets": "Radiographically assessable disease",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "radiographic assessability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy for malignancies other than pancreatic cancer completed > 5 years ago and is no evidence of the prior malignancy at time of study entry.",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy for malignancies other than pancreatic cancer completed > 5 years ago",
                    "criterion": "chemotherapy for non-pancreatic malignancies",
                    "requirements": [
                        {
                            "requirement_type": "completion time since chemotherapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of the prior malignancy at time of study entry",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "evidence of disease",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Awareness of the neoplastic nature of his/her disease and willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.",
            "criterions": [
                {
                    "exact_snippets": "Awareness of the neoplastic nature of his/her disease",
                    "criterion": "awareness of neoplastic nature of disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingly provide written, informed consent after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* 19 years of age or older.",
            "criterions": [
                {
                    "exact_snippets": "19 years of age or older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 19,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pathologically confirmed pancreatic adenocarcinoma. Participants must have resectable disease with no evidence of distant metastasis.",
            "criterions": [
                {
                    "exact_snippets": "Pathologically confirmed pancreatic adenocarcinoma",
                    "criterion": "pancreatic adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must have resectable disease",
                    "criterion": "disease resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectable",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of distant metastasis",
                    "criterion": "distant metastasis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Recognized acquired, hereditary, or congenital immunodeficiency disease including cellular immunodeficienciess, hypogammaglobulinemia, or dysgammaglobulinemia.",
            "criterions": [
                {
                    "exact_snippets": "Recognized acquired, hereditary, or congenital immunodeficiency disease",
                    "criterion": "immunodeficiency disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "acquired",
                                "hereditary",
                                "congenital"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "cellular immunodeficienciess",
                    "criterion": "cellular immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypogammaglobulinemia",
                    "criterion": "hypogammaglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "dysgammaglobulinemia",
                    "criterion": "dysgammaglobulinemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known HIV infection or active hepatitis B or C infection (concern for increased toxicity).",
            "criterions": [
                {
                    "exact_snippets": "Known HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or C infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A contra-indication to receiving digoxin therapy (e.g., AV block, sick sinus syndrome, bradycardia, hypersensitivity to digoxin or digitalis preparations).",
            "criterions": [
                {
                    "exact_snippets": "A contra-indication to receiving digoxin therapy",
                    "criterion": "contra-indication to digoxin therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "AV block",
                    "criterion": "AV block",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "sick sinus syndrome",
                    "criterion": "sick sinus syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "bradycardia",
                    "criterion": "bradycardia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to digoxin or digitalis preparations",
                    "criterion": "hypersensitivity to digoxin or digitalis preparations",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, adequately treated non-invasive carcinomas, or other cancers from which the participant has been disease-free least 5 years.",
            "criterions": [
                {
                    "exact_snippets": "Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, adequately treated non-invasive carcinomas, or other cancers from which the participant has been disease-free least 5 years.",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "adequately treated basal cell skin cancer",
                                "adequately treated squamous cell skin cancer",
                                "adequately treated non-invasive carcinomas",
                                "other cancers from which the participant has been disease-free at least 5 years"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant and nursing women (risk posed by chemotherapy agents). Female participants of childbearing potential must have a negative urine pregnancy test before receiving the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Pregnant and nursing women (risk posed by chemotherapy agents)",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Pregnant and nursing women (risk posed by chemotherapy agents)",
                    "criterion": "nursing status",
                    "requirements": [
                        {
                            "requirement_type": "nursing",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Female participants of childbearing potential must have a negative urine pregnancy test before receiving the first dose of study drug.",
                    "criterion": "urine pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease [e.g., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ulcerative colitis (UC), Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis (AS)].",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease [e.g., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ulcerative colitis (UC), Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis (AS)]",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unable to undergo staging laparoscopy, such as a prior history of multiple abdominal operations in which laparoscopy may not be technically feasible or might be potentially harmful.",
            "criterions": [
                {
                    "exact_snippets": "Unable to undergo staging laparoscopy",
                    "criterion": "ability to undergo staging laparoscopy",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior history of multiple abdominal operations",
                    "criterion": "history of multiple abdominal operations",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "laparoscopy may not be technically feasible",
                    "criterion": "technical feasibility of laparoscopy",
                    "requirements": [
                        {
                            "requirement_type": "technical feasibility",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "laparoscopy ... might be potentially harmful",
                    "criterion": "potential harm from laparoscopy",
                    "requirements": [
                        {
                            "requirement_type": "potential harm",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled inter-current illness including, but not limited to ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or serious, uncontrolled cardiac arrhythmia, that might jeopardize the ability of the participant to receive the therapy in this study with reasonable safety.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled inter-current illness",
                    "criterion": "inter-current illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "ongoing or active infection requiring intravenous antibiotics",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": [
                                "ongoing",
                                "active"
                            ]
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requiring intravenous antibiotics"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "serious, uncontrolled cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": "serious"
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}